Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr

Marie Louise Max Andersen, Lotte B Nielsen, Jannet Svensson, Sven Pörksen, Philip Hougaard, Craig Beam, Carla Greenbaum, Dorothy Becker, Jacob S Petersen, Lars Hansen, Henrik B Mortensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

OBJECTIVE: To clarify whether the rate of decline in stimulated C-peptide (SCP) from 2 to 15 months after diagnosis has changed over an interval of 27 yr. RESEARCH DESIGN AND METHODS: The rate of decline in SCP levels at 1, 2, 3, 6, 9, 12, and 15 months after diagnosis was compared in four paediatric cohorts from Scandinavian and European countries including 446 children with new onset type 1 diabetes (T1D, 1982-2004). Findings were evaluated against 78 children (2004-2009) from the TrialNet studies. RESULTS: The mean rate of decline [%/month (±SEM)] in SCP for a 10-yr-old child was 7.7%/month (±1.5) in the 1982-1985 Cohort, 6.3%/month (±1.7) in the 1995-1998 Cohort, 7.8%/month (±0.7) in the 1999-2000 Cohort, and 10.7%/month (±0.9) in the latest 2004-2005 Cohort (p = 0.05). Including the TrialNet Cohort with a rate of decline in SCP of 10.0%/month (±0.9) the differences between the cohorts are still significant (p = 0.039). The rate of decline in SCP was negatively associated with age (p < 0.0001), insulin antibodies (IA) (p = 0.003), and glutamic acid decarboxylase-65 (GAD65A) (p = 0.03) initially with no statistically significant effect of body mass index (BMI) Z-score at 3 months. Also, at 3 months the time around partial remission, the effect of age on SCP was significantly greater in children ≤5 yr compared with older children (p ≤ 0.0001). CONCLUSIONS: During the past 27 yr, initial C-peptide as well as the rate of C-peptide decline seem to have increased. The rate of decline was affected significantly by age, GAD65A, and IA, but not BMI Z-score or initial C-peptide.
OriginalsprogEngelsk
TidsskriftPediatric Diabetes
Vol/bind15
Udgave nummer5
Sider (fra-til)345-54
ISSN1399-543X
DOI
StatusUdgivet - aug. 2014

Fingeraftryk

Scandinavian and Nordic Countries
North America
Insulin Antibodies
Body Mass Index
Glutamate Decarboxylase
Pediatrics

Citer dette

Max Andersen, Marie Louise ; Nielsen, Lotte B ; Svensson, Jannet ; Pörksen, Sven ; Hougaard, Philip ; Beam, Craig ; Greenbaum, Carla ; Becker, Dorothy ; Petersen, Jacob S ; Hansen, Lars ; Mortensen, Henrik B. / Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. I: Pediatric Diabetes. 2014 ; Bind 15, Nr. 5. s. 345-54.
@article{5cdda0f66d4f4601adb223a013eac190,
title = "Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr",
abstract = "OBJECTIVE: To clarify whether the rate of decline in stimulated C-peptide (SCP) from 2 to 15 months after diagnosis has changed over an interval of 27 yr.RESEARCH DESIGN AND METHODS: The rate of decline in SCP levels at 1, 2, 3, 6, 9, 12, and 15 months after diagnosis was compared in four paediatric cohorts from Scandinavian and European countries including 446 children with new onset type 1 diabetes (T1D, 1982-2004). Findings were evaluated against 78 children (2004-2009) from the TrialNet studies.RESULTS: The mean rate of decline [{\%}/month (±SEM)] in SCP for a 10-yr-old child was 7.7{\%}/month (±1.5) in the 1982-1985 Cohort, 6.3{\%}/month (±1.7) in the 1995-1998 Cohort, 7.8{\%}/month (±0.7) in the 1999-2000 Cohort, and 10.7{\%}/month (±0.9) in the latest 2004-2005 Cohort (p = 0.05). Including the TrialNet Cohort with a rate of decline in SCP of 10.0{\%}/month (±0.9) the differences between the cohorts are still significant (p = 0.039). The rate of decline in SCP was negatively associated with age (p < 0.0001), insulin antibodies (IA) (p = 0.003), and glutamic acid decarboxylase-65 (GAD65A) (p = 0.03) initially with no statistically significant effect of body mass index (BMI) Z-score at 3 months. Also, at 3 months the time around partial remission, the effect of age on SCP was significantly greater in children ≤5 yr compared with older children (p ≤ 0.0001).CONCLUSIONS: During the past 27 yr, initial C-peptide as well as the rate of C-peptide decline seem to have increased. The rate of decline was affected significantly by age, GAD65A, and IA, but not BMI Z-score or initial C-peptide.",
author = "{Max Andersen}, {Marie Louise} and Nielsen, {Lotte B} and Jannet Svensson and Sven P{\"o}rksen and Philip Hougaard and Craig Beam and Carla Greenbaum and Dorothy Becker and Petersen, {Jacob S} and Lars Hansen and Mortensen, {Henrik B}",
note = "{\circledC} 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2014",
month = "8",
doi = "10.1111/pedi.12098",
language = "English",
volume = "15",
pages = "345--54",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Wiley-Blackwell Munksgaard",
number = "5",

}

Max Andersen, ML, Nielsen, LB, Svensson, J, Pörksen, S, Hougaard, P, Beam, C, Greenbaum, C, Becker, D, Petersen, JS, Hansen, L & Mortensen, HB 2014, 'Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr', Pediatric Diabetes, bind 15, nr. 5, s. 345-54. https://doi.org/10.1111/pedi.12098

Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. / Max Andersen, Marie Louise; Nielsen, Lotte B; Svensson, Jannet; Pörksen, Sven; Hougaard, Philip; Beam, Craig; Greenbaum, Carla; Becker, Dorothy; Petersen, Jacob S; Hansen, Lars; Mortensen, Henrik B.

I: Pediatric Diabetes, Bind 15, Nr. 5, 08.2014, s. 345-54.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr

AU - Max Andersen, Marie Louise

AU - Nielsen, Lotte B

AU - Svensson, Jannet

AU - Pörksen, Sven

AU - Hougaard, Philip

AU - Beam, Craig

AU - Greenbaum, Carla

AU - Becker, Dorothy

AU - Petersen, Jacob S

AU - Hansen, Lars

AU - Mortensen, Henrik B

N1 - © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2014/8

Y1 - 2014/8

N2 - OBJECTIVE: To clarify whether the rate of decline in stimulated C-peptide (SCP) from 2 to 15 months after diagnosis has changed over an interval of 27 yr.RESEARCH DESIGN AND METHODS: The rate of decline in SCP levels at 1, 2, 3, 6, 9, 12, and 15 months after diagnosis was compared in four paediatric cohorts from Scandinavian and European countries including 446 children with new onset type 1 diabetes (T1D, 1982-2004). Findings were evaluated against 78 children (2004-2009) from the TrialNet studies.RESULTS: The mean rate of decline [%/month (±SEM)] in SCP for a 10-yr-old child was 7.7%/month (±1.5) in the 1982-1985 Cohort, 6.3%/month (±1.7) in the 1995-1998 Cohort, 7.8%/month (±0.7) in the 1999-2000 Cohort, and 10.7%/month (±0.9) in the latest 2004-2005 Cohort (p = 0.05). Including the TrialNet Cohort with a rate of decline in SCP of 10.0%/month (±0.9) the differences between the cohorts are still significant (p = 0.039). The rate of decline in SCP was negatively associated with age (p < 0.0001), insulin antibodies (IA) (p = 0.003), and glutamic acid decarboxylase-65 (GAD65A) (p = 0.03) initially with no statistically significant effect of body mass index (BMI) Z-score at 3 months. Also, at 3 months the time around partial remission, the effect of age on SCP was significantly greater in children ≤5 yr compared with older children (p ≤ 0.0001).CONCLUSIONS: During the past 27 yr, initial C-peptide as well as the rate of C-peptide decline seem to have increased. The rate of decline was affected significantly by age, GAD65A, and IA, but not BMI Z-score or initial C-peptide.

AB - OBJECTIVE: To clarify whether the rate of decline in stimulated C-peptide (SCP) from 2 to 15 months after diagnosis has changed over an interval of 27 yr.RESEARCH DESIGN AND METHODS: The rate of decline in SCP levels at 1, 2, 3, 6, 9, 12, and 15 months after diagnosis was compared in four paediatric cohorts from Scandinavian and European countries including 446 children with new onset type 1 diabetes (T1D, 1982-2004). Findings were evaluated against 78 children (2004-2009) from the TrialNet studies.RESULTS: The mean rate of decline [%/month (±SEM)] in SCP for a 10-yr-old child was 7.7%/month (±1.5) in the 1982-1985 Cohort, 6.3%/month (±1.7) in the 1995-1998 Cohort, 7.8%/month (±0.7) in the 1999-2000 Cohort, and 10.7%/month (±0.9) in the latest 2004-2005 Cohort (p = 0.05). Including the TrialNet Cohort with a rate of decline in SCP of 10.0%/month (±0.9) the differences between the cohorts are still significant (p = 0.039). The rate of decline in SCP was negatively associated with age (p < 0.0001), insulin antibodies (IA) (p = 0.003), and glutamic acid decarboxylase-65 (GAD65A) (p = 0.03) initially with no statistically significant effect of body mass index (BMI) Z-score at 3 months. Also, at 3 months the time around partial remission, the effect of age on SCP was significantly greater in children ≤5 yr compared with older children (p ≤ 0.0001).CONCLUSIONS: During the past 27 yr, initial C-peptide as well as the rate of C-peptide decline seem to have increased. The rate of decline was affected significantly by age, GAD65A, and IA, but not BMI Z-score or initial C-peptide.

U2 - 10.1111/pedi.12098

DO - 10.1111/pedi.12098

M3 - Journal article

VL - 15

SP - 345

EP - 354

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 5

ER -